A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1634-1641

  Huang, Hui ^a,b   Menefee, Michael ^a,c   Edgerly, Maureen ^a   Zhuang, Sen ^a,d   Kotz, Herb ^a   Poruchynsky, Marianne ^a   Huff, Lyn Mickley ^a   Bates, Susan ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b North California Kaiser Permanente ^*  (United States)

^c MAYO CLINIC   (United States)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DIPHENHYDRAMINE; INTERLEUKIN 12; INTERLEUKIN 2; IXABEPILONE; RANITIDINE; SORAFENIB; SUNITINIB; THALIDOMIDE; VON HIPPEL LINDAU PROTEIN;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE SEQUENCE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE METASTASIS; SURVIVAL TIME; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; EPOTHILONES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TUBULIN;

EID: 77649106272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0379     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
4. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006;176:2397-400;discussion 2400.
5. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-21.
6. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
7. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
8. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-6.
9. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
10. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:1272-8.
11. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80.
12. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
15. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
16. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997;272:2534-41.
17. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
18. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
19. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
20. Chou TC, O'Connor OA, Tong WP, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A 1998;95:15798-802.
21. Chou TC, O'Connor OA, Tong WP, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A 2001;98:8113-8.
22. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
25. Zhuang SH, Hung YE, Hung L, et al. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res 2007;13:7480-6.
26. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.
27. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
28. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
29. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
30. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
31. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
32. Breathnach OS, Georgiadis MS, Schuler BS, et al. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin Cancer Res 2000;6:2670-6.
33. Cocconi G, Mambrini A, Quarta M, et al. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 2000;88:2731-8.
34. Anderson SE, O'Reilly EM, Kelsen DP, Ilson DH. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 2003;21:512-6.
35. Langer CJ, Li Y, Jennings T, et al. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 2004;22:823-31.
36. Maier-Lenz H, Hauns B, Haering B, et al. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. Semin Oncol 1997;24:S19-16-19.
37. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T. A phase II study of ixabepilone (BMS-247550) in metastatic renalcell carcinoma. Cancer Biol Ther 2007;6:490-3.
38. Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol 1997;40:245-50.
39. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther 2008;7:630-7.
40. Einzig AI, Gorowski E, Sasloff J, Wiernik PH. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 1991;9:133-6.
41. Bruntsch U, Heinrich B, Kaye SB, et al. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 1994;30A:1064-7.
42. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995;95:2205-14.
43. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.